ALBANY, NY – JUNE 5, 2023 – This afternoon, the New York State Senate passed legislation that would ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it.
AUSTIN, TX – MAY 30, 2023 – Yesterday, Texas Governor Greg Abbott signed Senate Bill 989 into law, making Texas the 11th state to expand access to biomarker testing. New York is considering comparable legislation through Assembly Bill 1673 / Senate Bill 1196.
SAINT PAUL, Minn. – Today, Governor Tim Walz signed legislation that will ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it.
ALBANY, NY – MAY 19, 2023 – Every year on May 20, patients and providers celebrate the invaluable work of clinical trials in the effort to eradicate all suffering and death from cancer.
ALBANY, NY – MAY 17, 2023 – Earlier today, oncologists and cancer survivors from across New York gathered at the Capitol to answer lawmakers’ questions about biomarker testing and ask for their support of Senate Bill 1196 / Assembly Bill 1673. This legislation, which is being sponsored by Asm.
The American Cancer Society Cancer Action Network Thanks Lawmakers for Passing Legislation That Expands Access to Precision Medicine.
ALBANY, NY – MAY 15, 2023 – Oncologists and cancer survivors from across New York will gather at the Capitol building on Wednesday, May 17 to answer lawmakers’ questions about biomarker testing and ask for their support of Senate Bill 1196 / Assembly Bill 1673, which aim to improve New Yorkers’ a
ATLANTA, GA – MAY 1, 2023 – Tomorrow, Gov. Brian Kemp will hold a ceremonial bill signing for legislation that will increase insurance coverage for biomarker testing – thus making this form of precision medicine available to more Georgians.
ALBANY, NY –APRIL 21, 2023 – Cancer survivors, their families and caregivers from across New York will gather at the Capitol building on Tuesday, April 25 to ask legislators to support Senate Bill 1196 / Assembly Bill 1673, which aims to improve New Yorkers’ access to biomarker testing – a tool t